Bruker (Nasdaq: BRKR) reported Q2 2026 revenue of $838.5 million, up 5.2% year over year, while GAAP diluted EPS swung to a loss of $0.41 from earnings of $0.05 and non-GAAP diluted EPS rose to $0.49 from $0.32. Organic growth returned, bookings improved and adjusted margins expanded, but a $134.9 million non-cash goodwill impairment pushed the company to a GAAP operating loss.
Core Financial Results
Organic revenue grew 2.8%, or 3.4% excluding tariff refunds. Acquisitions contributed 1.5 percentage points to growth, while favorable currency translation added 0.9 points; constant-exchange-rate revenue increased 4.3%.
The quarter showed a sharp divergence between GAAP and adjusted profitability. The impairment drove the reported loss, while non-GAAP operating income increased by about 64.6% and non-GAAP operating margin expanded by 5.1 percentage points.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| Revenue | $838.5 million | $797.4 million | +5.2% |
| GAAP gross profit and margin | $416.0 million; 49.6% | $357.9 million; 44.9% | About +16.2%; +4.7 pts |
| GAAP operating income (loss) and margin | $(65.3) million; (7.8)% | $11.9 million; 1.5% | Swung to loss; -9.3 pts |
| Non-GAAP operating income and margin | $118.5 million; 14.1% | $72.0 million; 9.0% | About +64.6%; +5.1 pts |
| GAAP net income (loss) attributable to common shareholders | $(62.9) million | $7.6 million | Swung to loss |
| GAAP diluted EPS | $(0.41) | $0.05 | Swung to loss |
| Non-GAAP diluted EPS | $0.49 | $0.32 | About +53.1% |
Business and Segment Performance
Bruker Scientific Instruments, or BSI, generated organic bookings growth of 10% and a book-to-bill ratio above 1.0, meaning bookings exceeded recognized revenue during the quarter. BSI organic revenue grew 2.3%, while BEST posted the fastest reported and organic revenue growth.
Within BSI, CALID was the clearest revenue growth driver. BioSpin was nearly unchanged, while Nano recorded moderate growth.
| Segment | Q2 2026 revenue | Q2 2025 revenue | Year-over-year change |
|---|---|---|---|
| BSI total | $767.3 million | $733.2 million | +4.7%; +2.3% organic |
| Bruker BioSpin | $195.7 million | $195.3 million | About +0.2% |
| Bruker CALID | $310.3 million | $285.8 million | About +8.6% |
| Bruker Nano | $261.3 million | $252.1 million | About +3.6% |
| BEST | $74.2 million | $66.3 million | +11.9%; +8.9% organic |
Geographically, revenue increased by about 13.3% in Europe and 11.4% in the United States, while Asia-Pacific revenue declined by about 10.2%. Management reported strong bookings for semiconductor tools, energy research and biopharma products. U.S. academic demand remained soft, but academic and government bookings increased strongly in Europe and China.
A $134.9 Million Impairment Masked Underlying Margin Expansion
The non-cash goodwill impairment was the main reason GAAP operating expenses rose to $481.3 million from $346.0 million. In the GAAP-to-non-GAAP reconciliation, the impairment represented an adjustment of $0.88 per diluted share and accounted for most of the difference between the GAAP loss and adjusted earnings.
Underlying operating indicators improved. Cost of revenue fell to $422.5 million from $439.5 million even as revenue increased, lifting GAAP gross margin to 49.6%. Non-GAAP gross margin also rose to 52.1% from 48.6%. SG&A expense increased to $238.9 million from $231.4 million, slower than revenue growth, while R&D expense declined to $94.3 million from $100.2 million.
The reconciliation also removed a $27.6 million unrealized investment gain from adjusted results, so the GAAP-to-non-GAAP bridge was not solely attributable to the impairment. Other adjustments included acquired-intangible amortization, restructuring and acquisition-related costs.
FY2026 Guidance
Bruker described the outlook revision as a currency-and-tax update rather than a change to its operational assumptions. The expected foreign-currency revenue tailwind was reduced from approximately 1.5% to 0.5%, but the company reiterated its non-GAAP EPS range.
| Metric | Latest FY2026 guidance | Change or context |
|---|---|---|
| Revenue | $3.54 billion to $3.57 billion | 3% to 4% growth from FY2025 revenue of $3.44 billion |
| Organic revenue growth | 1% to 2% | No operational change stated |
| M&A revenue growth | Approximately 1.5% | Included in reported growth outlook |
| Constant-exchange-rate revenue growth | 2.5% to 3.5% | Excludes currency translation |
| Currency translation effect | Approximately +0.5% | Previously approximately +1.5% |
| Non-GAAP diluted EPS | $2.10 to $2.15 | Reiterated; 15% to 17% growth and about $0.10 of currency headwind |
| Effective non-GAAP tax rate | 27.5% | Updated tax assumption; prior rate not provided |
The outlook is based on exchange rates as of June 30, 2026. Management also expressed confidence in a gradual market recovery and expects organic margin expansion and non-GAAP EPS growth in 2027, although it did not provide quantified 2027 guidance.
Recent Insider Transactions
The supplied six-month insider summary reports 60,086 shares acquired across 17 transactions and 12,000 shares sold across six transactions, resulting in net acquisitions of 48,086 shares. That represented 0.10% of total insider holdings of approximately 41.04 million shares; because the acquisitions included derivative conversions and stock grants, the figure should not be interpreted entirely as discretionary open-market buying.
The 10 latest entries were all reported as direct ownership transactions. Most involved recurring derivative conversions and sales by officer Mark Munch, plus one stock award to director Thierry Bernard.
| Date | Insider | Transaction | Price per share | Reported value |
|---|---|---|---|---|
| July 15, 2026 | Mark Robert Munch, Officer | Derivative security conversion | $22.19 | $44,380 |
| July 15, 2026 | Mark Robert Munch, Officer | Sale | $60.25 | $120,500 |
| June 15, 2026 | Mark Robert Munch, Officer | Derivative security conversion | $22.19 | $44,380 |
| June 15, 2026 | Mark Robert Munch, Officer | Sale | $54.76 | $109,520 |
| May 15, 2026 | Mark Robert Munch, Officer | Derivative security conversion | $22.19 | $44,380 |
| May 15, 2026 | Mark Robert Munch, Officer | Sale | $43.90 | $87,800 |
| May 15, 2026 | Thierry Bernard, Director | Stock award | $0.00 | $0 |
| April 15, 2026 | Mark Robert Munch, Officer | Derivative security conversion | $22.19 | $44,380 |
| April 15, 2026 | Mark Robert Munch, Officer | Sale | $39.90 | $79,800 |
| March 13, 2026 | Mark Robert Munch, Officer | Derivative security conversion | $22.19 | $44,380 |
Risks Investors Should Watch
- Soft U.S. academic demand: Continued weakness could constrain BSI organic growth, even as academic and government bookings improve in Europe and China.
- Asia-Pacific revenue pressure: Regional revenue declined by about 10.2%. Stronger bookings in China will need to convert into recognized revenue to offset this weakness.
- Currency and tariff effects: Bruker reduced its expected currency revenue tailwind, and its FY2026 EPS outlook includes an approximately $0.10 currency headwind. Tariff refunds also reduced reported organic growth by 0.6 percentage points in Q2.
- GAAP earnings volatility: The goodwill impairment created a substantial gap between GAAP and adjusted results, highlighting the importance of monitoring future impairments and acquisition-related adjustments.
Conclusion
Bruker returned to organic revenue growth in Q2 2026, with BSI bookings exceeding revenue and BEST and CALID leading segment growth. Cost control and improved gross margin supported a sizable increase in adjusted operating profit, although the goodwill impairment caused a GAAP loss. The main follow-up points are the pace of recovery in academic demand, the conversion of stronger bookings into revenue, Asia-Pacific performance and the effect of less favorable currency conditions on FY2026 results.
Find out more
Comments